Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Granted FDA Fast Track Designation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Biogen's (BIIB) Aducanumab Appears Further De-Risked - Jefferies
September 2, 2016 7:44 AM EDTJefferies analyst Brian Abrahams saying Biogen's (NASDAQ: BIIB) aducanumab appears to be further de-risked based tidbit tucked away at the very brief PR the company issued yesterday evening on Fast Track status.
"... we believe new data from the ph.Ib dose titration arms is confirming aducanumab's efficacy observed in the prior arms, helping additionally de-risk the program," Abrahams said.
Abrahams expects upside for shares on this development.
The analyst notes a clear suggestions... More
